scispace - formally typeset
P

Paola Ghiorzo

Researcher at University of Genoa

Publications -  134
Citations -  6645

Paola Ghiorzo is an academic researcher from University of Genoa. The author has contributed to research in topics: CDKN2A & Germline mutation. The author has an hindex of 37, co-authored 122 publications receiving 5824 citations. Previous affiliations of Paola Ghiorzo include University of Leeds & St James's University Hospital.

Papers
More filters
Journal ArticleDOI

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

Corine Bertolotto, +98 more
- 01 Dec 2011 - 
TL;DR: A germline missense substitution in MITF (Mi-E318K) is identified that occurred at a significantly higher frequency in genetically enriched patients affected with melanoma, RCC or both cancers, when compared with controls and provides insights into the link between SUMOylation, transcription and cancer.
Journal ArticleDOI

Genome-wide association study identifies three loci associated with melanoma risk.

D. Timothy Bishop, +54 more
- 05 Jul 2009 - 
TL;DR: Despite wide variation in allele frequency, these genetic variants show notable homogeneity of effect across populations of European ancestry living at different latitudes and show independent association to disease risk.
Journal ArticleDOI

High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL

Alisa M. Goldstein, +99 more
- 15 Oct 2006 - 
TL;DR: This GenoMEL study provides the most extensive characterization of mutations in high-risk melanoma susceptibility genes in families with three or more melanoma patients yet available and there was little evidence for an association between CDKN2A mutations and NST, but there was a marginally significant association between NST and ARF.
Journal ArticleDOI

Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma‐prone families from three continents

TL;DR: The variation in CDKN2A mutations for the four features across continents is consistent with the lower melanoma incidence rates in Europe and higher rates of sporadic melanoma in Australia, which reflects the divergent spectrum of mutations in families from Australia versus those from North America and Europe.